Vanda Pharmaceuticals Inc. (VNDA) is set to face a pivotal FDA decision on February 21, 2026, for its drug candidate Bysanti.
Bysanti is proposed for the treatment of bipolar I disorder and schizophrenia, two major psychiatric indications with significant unmet needs. This drug candidate (milsaperidone) is an active metabolite of iloperidone, marketed as Fanapt.
For comments and feedback contact: editorial@rttnews.com
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.